NCT01703117View on ClinicalTrials.gov

Riluzole in Mild Alzheimer's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

May 26, 2020

Study Completion Date

May 26, 2020

Conditions
Alzheimer's Disease
Interventions
DRUG

Riluzole

20-22 subjects between the ages of 60-85 will receive study drug.

DRUG

Placebo

20-22 subjects between the ages of 60-85 will receive placebo

Trial Locations (2)

10029

Icahn School of Medicine at Mount Sinai, New York

10065

The Rockefeller University, New York

All Listed Sponsors
collaborator

Rockefeller University

OTHER

lead

Icahn School of Medicine at Mount Sinai

OTHER

NCT01703117 - Riluzole in Mild Alzheimer's Disease | Biotech Hunter | Biotech Hunter